Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Humanwell Healthcare (Group) Co's Debt-to-Equity or its related term are showing as below:
SHSE:600079'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.46 Med: 0.84 Max: 1.46
Current: 0.46
During the past 13 years, the highest Debt-to-Equity Ratio of Humanwell Healthcare (Group) Co was 1.46. The lowest was 0.46. And the median was 0.84.
SHSE:600079's Debt-to-Equity is ranked worse than 66.21% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs SHSE:600079: 0.46
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Humanwell Healthcare (Group) Co Debt-to-Equity Related Terms
Humanwell Healthcare (Group) Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humanwell Healthcare (Group) Co Debt-to-Equity Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Humanwell Healthcare (Group) Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Humanwell Healthcare (Group) Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Humanwell Healthcare (Group) Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Humanwell Healthcare (Group) Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humanwell Healthcare (Group) Co (SHSE:600079) has a Debt-to-Equity of 0.46 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Humanwell Healthcare (Group) Co and its competitors. This is 45% below median its historical median of 0.84. Over the past decade, Humanwell Healthcare (Group) Co's Debt-to-Equity has ranged from 0.46 to 1.46. According to the industry distribution chart, Humanwell Healthcare (Group) Co ranks #537 out of 811 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is Humanwell Healthcare (Group) Co's Debt-to-Equity too high?
Humanwell Healthcare (Group) Co's current Debt-to-Equity of 0.46 is 45% below median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 1.46. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Humanwell Healthcare (Group) Co's value of 0.46 is 64.3% above this industry median. Based on the distribution chart, Humanwell Healthcare (Group) Co ranks #537 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Humanwell Healthcare (Group) Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Humanwell Healthcare (Group) Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Humanwell Healthcare (Group) Co ranks #537 out of 811 companies for Debt-to-Equity. This places Humanwell Healthcare (Group) Co in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Humanwell Healthcare (Group) Co's value of 0.46 is 64.3% above this benchmark. Historically, Humanwell Healthcare (Group) Co's own Debt-to-Equity has ranged from 0.46 to 1.46 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.28, Humanwell Healthcare (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Humanwell Healthcare (Group) Co's current Debt-to-Equity of 0.46 is 64.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Humanwell Healthcare (Group) Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Humanwell Healthcare (Group) Co's current Debt-to-Equity is 0.46, which is 45% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humanwell Healthcare (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co (SHSE:600079) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥22.17, compared to a current price of ¥17.85 — trading 19.5% below its estimated fair value. The current Debt-to-Equity is 0.46, which is 45% below median its 10-year median of 0.84 and 64.3% above the Drug Manufacturers industry median of 0.28. Humanwell Healthcare (Group) Co's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Humanwell Healthcare (Group) Co (SHSE:600079), the current Debt-to-Equity is 0.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Humanwell Healthcare (Group) Co (SHSE:600079) Overvalued in 2026?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co stock appears to be undervalued.
The current stock price of ¥17.85 is trading 19.5% below its estimated GF Value™ of ¥22.17.
GuruFocus considers Humanwell Healthcare (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600079:
Debt-to-Equity: 0.46 (45% below median its 10-year median of 0.84)
GF Value™: ¥22.17 vs. price of ¥17.85 (19.5% below fair value)
Industry Position: 64.3% above the Drug Manufacturers median (#537 of 811)
No single metric tells the full story. See the SHSE:600079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. It provides medicinal products including fertility-regulating drugs, Uyghur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries.
64GF Score
Get the complete analysis for SHSE:600079
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600079 has been successfully added to your 
